PT  - JOURNAL ARTICLE
AU  - Klein, Hadar
AU  - Asseo, Kim
AU  - Karni, Noam
AU  - Benjamini, Yuval
AU  - Nir-Paz, Ran
AU  - Muszkat, Mordechai
AU  - Israel, Sarah
AU  - Niv, Masha Y.
TI  - Onset, duration, and persistence of taste and smell changes and other COVID-19 symptoms: longitudinal study in Israeli patients
AID  - 10.1101/2020.09.25.20201343
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.25.20201343
4099  - http://medrxiv.org/content/early/2020/09/27/2020.09.25.20201343.short
4100  - http://medrxiv.org/content/early/2020/09/27/2020.09.25.20201343.full
AB  - Objectives The multifaceted disease manifestation of COVID-19 requires longitudinal characterization of symptoms, to aid with screening and disease management.Methods Phone interviews and follow-ups were completed with 112 mild COVID-19 RT-PCR-positive adult patients, over a six weeks period.Results More than one symptom at disease onset was experienced by ∼70 of the patients. Over one third of the patients experienced fever, dry cough, headache, or muscle ache as the first symptom. If fatigue was reported, it was usually the first symptom to appear. Smell and taste changes had occurred 3.9 ± 5.4 and 4.6 ± 5.7 days (mean ± SD) since disease onset and emerged as first symptoms in 15% and 18% of patients, respectively. Fever was the shortest lasting symptom (5.8 ± 8.6 days (mean ± SD), and smell and taste changes were the longest-lasting symptoms (24.3 ± 22.9 days and 19.4 ± 19.1 (mean ± SD), respectively), with longer smell recovery correlated with smell change severity. In one third of patients who reported cough, smell and taste changes, these symptoms persisted after negative RT-PCR tests.Conclusions Each symptom can occur as first or later, some are more likely to appear as firsts, and typically more than one symptom occurs at disease onset. The severity of olfactory change is associated with its recovery time. Lack of chemosensory recuperation in recovered patients is common. These findings can aid patients through their illness and provide expected recovery patterns.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMYN is supported by Israel Science Foundation (ISF) grant #1129/19. HK is a recipient of the Uri Zehavi Scholarship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with Helsinki committee and the required ethics approval was granted (reference number HMO-0236-20).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.CDCCenters for Disease Control and PreventionSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2SDStandard DeviationGCCRGlobal Consortium for Chemosensory ResearchRT-PCRReal Time Polymerase Chain ReactionURIUpper Respiratory tract Infections